UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The ~~Securities Exchange Act of 1934~~

~~Date~~Securities ofExchange ~~Report~~Act ~~(Date~~ of 1934 ~~earliest event reported): June 29, 2012~~

Date of Report (Date of earliest event reported): July 2, 2012

CATALYST HEALTH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-31014	52-2181356
(State or other jurisdiction	(Commission	(IRS Employer
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)	File Number)	Identification No.)
800 King Farm Boulevard Rockville, Maryland		20850
(Address of Principal Executive Offices)		(Zip Code)

800 King Farm Boulevard

Rockville, Maryland

20850

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (301) 548-2900

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 81.~~01.~~02 ~~Other~~Termination ~~Events~~of a Material Definitive Agreement.

On ~~June~~July 292, 2012, Catalyst Health Solutions, Inc., a Delaware corporation (the “Company” or “Catalyst”), ~~entered~~repaid ~~into~~all anamounts ~~Amendment~~(including toprincipal, ~~Agreement~~interest and ~~Plan of Merger (the “Amendment”~~fees) toaccrued ~~amend~~and outstanding under that certain ~~Agreement~~Revolving Credit and ~~Plan~~Term ofLoan ~~Merger,~~Agreement dated as of ~~April~~August 174, ~~2012~~2010 (among the ~~“Merger~~ ~~Agreement”)~~Company, byas ~~and among Catalyst~~borrower, ~~SXC~~the ~~Health~~lenders ~~Solutions~~from ~~Corp.,~~time ato ~~corporation~~time ~~organized~~party ~~under~~thereto, ~~the~~Wells ~~laws~~Fargo ~~of the Yukon Territory~~Bank, ~~Canada~~National ~~(“SXC”),~~Association ~~SXC~~and ~~Health~~Bank ~~Solutions~~of America, ~~Inc~~N. ~~(“US Corp~~A.”), as ~~Catamaran~~Co-Syndication ~~I Corp. (“Merger Sub”) and Catamaran II LLC. The Merger Agreement provides~~Agents, ~~among~~JPMorgan ~~other~~Chase ~~things~~Bank, ~~that,~~N.A. ~~upon the terms~~ and ~~subject~~Citizens toBank ~~the~~of ~~conditions set forth therein~~Pennsylvania, ~~Merger~~as ~~Sub~~Co-Documentation ~~will~~Agents ~~merge with~~ and ~~into~~SunTrust ~~Catalyst~~Bank, ~~with Catalyst surviving~~ as aAdministrative ~~wholly-owned~~Agent ~~subsidiary of US Corp.~~ (the “~~Surviving~~Credit ~~Corporation~~Agreement”). ~~Pursuant~~ toThe ~~the~~Credit ~~Amendment, a ministerial change has been made to the Merger~~ Agreement ~~and~~was ~~form~~terminated ofeffective ~~amended and restated certificate of incorporation of the Surviving Corporation attached~~ as ~~Exhibit A thereto to reduce the par value~~ of ~~the common stock of the Surviving Corporation. The Amendment does not affect the amount of consideration that holders of Catalyst stock~~ ~~would be entitled to receive for their shares upon completion of the merger. A copy of the Amendment is attached as Exhibit~~ July 2.1, ~~and is incorporated herein by reference~~2012.

~~* * * * * * * *~~Item 2.01 Completion of Acquisition or Disposition of Assets

Effective as of 4:01 p.m. Eastern Time on July 2, 2012 (the “Effective Time”), a wholly-owned subsidiary of SXC Health Solutions Corp., a corporation organized under the laws of the Yukon Territory, Canada (“SXC”), was merged with and into the Company (the “Merger”) pursuant to that certain Agreement and Plan of Merger, dated as of April 17, 2012 and as amended on June 29, 2012, among SXC, SXC Health Solutions, Inc., a Texas corporation and wholly-owned subsidiary of SXC (“US Corp.”), Catamaran I Corp., a Delaware corporation and a direct wholly-owned subsidiary of US Corp. (“Merger Sub”), Catamaran II LLC, a Delaware limited liability company and wholly-owned subsidiary of US Corp. (“Merger LLC”), and the Company (as amended, the “Merger Agreement”). As a result of the Merger, the Company became an indirect, wholly-owned subsidiary of SXC. Following the Merger, the Company merged (the “Subsequent Merger”) into Merger LLC, with Merger LLC continuing as the surviving company under the name Catamaran Health Solutions, LLC.

As a result of the Merger, each share of common stock, par value $0.01 per share, of the Company (“Company Common Stock”) outstanding immediately prior to the Effective Time (other than shares of Company Common Stock for which appraisal rights were properly exercised or shares of Company Common Stock owned by the Company, SXC, US Corp., Merger Sub, Merger LLC or any of their respective wholly-owned subsidiaries) was converted into the right to receive (i) $28.00 in cash without interest and (ii) 0.6606 of a share of common stock (“SXC Common Stock”), no par value per share, of SXC (the “Merger Consideration”). No fractional shares of SXC Common Stock were issued in the Merger, and the Company’s stockholders will receive cash in lieu of fractional shares, if any, of SXC Common Stock. The issuance of SXC Common Stock in connection with the Merger, as described above, was registered under the Securities Act of 1933, as amended, pursuant to the registration statement on Form S-4 (File No. 333- 181189) (the “Registration Statement”), filed with the Securities and Exchange Commission (the “SEC”) and declared effective on June 1, 2012.

~~Catalyst~~Each ~~Forward~~option ~~Looking~~to ~~Statements~~purchase Company Common Stock granted under a Company stock plan that was outstanding immediately prior to the Effective Time was assumed by SXC and became an option to purchase SXC Common Stock, on the same terms and conditions as the Company stock option (but taking into account any changes to the option, including any acceleration, lapse or other vesting, provided in the Company stock plan or related award documents by reason of the Merger). The number of shares of SXC Common Stock subject to each such converted stock option equals the number of shares of Company Common Stock subject to such Company stock option, multiplied by the option exchange ratio, rounded down to the nearest whole share of SXC common stock. The exercise price per share for each such converted stock option equals the per share exercise price specified in such Company stock option divided by the option exchange ratio (rounded up to the nearest cent). The “option exchange ratio” is equal to 0.9513 , which equals the sum of 0.6606 plus the fraction obtained by dividing $28.00 by the average per share last reported sale price of SXC common stock on NASDAQ over the five trading days preceding the Effective Time.

~~Certain~~In ~~statements~~connection ~~may~~with ~~contain~~the ~~certain forward-looking statements including~~Merger, ~~without~~each ~~limitation,~~share ~~statements~~of ~~concerning~~restricted ~~Catalyst’s~~stock ~~operations,~~granted ~~economic~~under ~~performance~~a ~~and~~Company ~~financial~~stock ~~condition. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “~~plan,” ~~“estimate,” “intend,” “predict,” “potential,” “continue,”~~ and ~~the~~outstanding ~~negatives~~immediately ofprior ~~these words and other similar expressions generally identify forward-looking statements. In addition~~ to ~~Catalyst’s expectations or estimates of a combined company’s future performance or matters relating to~~ the ~~proposed~~Effective ~~transaction~~Time ~~with~~became ~~SXC,~~fully ~~these~~vested ~~forward-looking statements may include statements addressing Catalyst’s operations~~ and ~~Catalyst’s~~at ~~financial~~the ~~performance.~~Effective ~~Readers~~Time ~~are cautioned not to place undue~~was ~~reliance~~cancelled on these forward-looking statements, which, among other things, speak only as of their dates. These forward-looking statements are based largely on Catalyst’s current expectations and are based on a number of risks and uncertainties, including, without limitation, (i) general adverse economic conditions, (ii) changes in ~~governmental~~exchange ~~laws~~for ~~and~~the ~~regulations,~~right ~~(iii) Catalyst’s ability~~ to ~~compete~~receive ~~effectively in~~ the ~~pharmacy~~Merger ~~benefit management industry, (iv)~~Consideration. ~~Catalyst’s~~In ~~relationships~~connection with ~~key clients, pharmacy network affiliations and various pharmaceutical manufacturers and rebate intermediaries, (v) changes in industry pricing benchmarks, (vi) uncertainties relating to~~ the ~~transition~~ ~~and integration of completed and future acquisitions and/or expansion opportunities~~Merger, ~~(vii) Catalyst’s~~each ~~current~~award ~~level~~ of ~~indebtedness~~performance ~~and~~share ~~any~~units future indebtedness Catalyst may incur; (viii) disruption in Catalyst’s operations, (ix) unanticipated changes in Catalyst’s ability to execute its growth strategy, (x) generic utilization levels, (xi) insufficient insurance coverage to cover costs associated with ~~litigation, (xii) Catalyst’s~~respect ~~ability~~ to ~~accurately~~shares ~~estimate how much future revenue Catalyst will generate, as well as the level~~ of ~~implementation~~Company ~~and~~Common ~~transaction~~Stock ~~costs~~granted ~~that Catalyst will incur,~~ under ~~newly~~a ~~commenced~~Company ~~PBM~~stock ~~agreements~~plan ~~and~~that ~~other~~was ~~risks and~~outstanding ~~uncertainties~~immediately ~~discussed~~prior into ~~Catalyst’s filings with~~ the ~~SEC,~~Effective ~~including~~Time ~~Catalyst’s~~became ~~Annual~~fully ~~Report~~vested onat ~~Form 10-K~~100% ~~and~~of ~~quarterly reports on Form 10-Q. Actual results could differ materially from results referred to in~~ the ~~forward-looking~~ ~~statements.~~target Innumber ~~light~~ of ~~these~~performance ~~risks~~share ~~and~~units ~~uncertainties,~~subject ~~there can be no assurances that the results referred~~ to insuch ~~the~~performance ~~forward-looking~~share ~~statements~~unit ~~contained herein will, in fact, occur~~award. ~~Catalyst~~Such ~~undertakes~~performance noshare ~~obligation~~unit toawards ~~revise~~were ~~any forward-looking~~cancelled ~~statements~~ in ~~order~~exchange tofor ~~reflect events or circumstances that may arise after~~ the ~~date~~right ~~hereof. Readers are urged~~ to ~~carefully review and consider the various disclosures made in Catalyst’s other filings with the SEC that attempt~~receive ~~to advise interested parties of~~ the ~~risks~~Merger ~~and factors that may affect Catalyst’s business~~Consideration.

~~Transaction~~In ~~Forward-Looking~~connection ~~Statements~~with the Merger, certain unexpired and unexercised Company warrants issued pursuant to a stock purchase agreement, dated as of June 18, 2004 were assumed by SXC and became a warrant to purchase the number of shares of SXC Common Stock (decreased to the nearest full share) determined by multiplying (i) the number of shares of Company Common Stock subject to such Company warrant immediately prior to the Effective Time by (ii) the option exchange ratio, at an exercise price per share of SXC Common Stock (rounded up to the nearest cent) equal to the exercise price per share of Company Common Stock under such Company warrant immediately prior to the Effective Time divided by the option exchange ratio. In addition, certain unexpired and unexercised Company warrants issued pursuant to a stock purchase agreement, dated as of August 25, 2010 were cancelled and converted into the right to receive, upon payment of the aggregate exercise price of such warrant, the combination of (x) the product of the per share cash amount (without interest, and subject to deduction for any required withholding taxes), multiplied by the number of shares of the Company Common Stock

In addition, numerous factors could cause actual results with respect to the proposed transaction with SXC to differ materially from those in the forward-looking statements, including without limitation, the possibility that the expected efficiencies and cost savings from the proposed transaction will not be realized, or will not be realized within the expected time period; the risk

~~that~~subject ~~the SXC and Catalyst businesses will not be integrated successfully; the ability~~ to ~~obtain~~such ~~governmental~~warrant ~~approvals~~as of ~~the~~immediately ~~proposed~~prior ~~transaction~~to on the ~~proposed~~Effective ~~terms~~Time, and ~~schedule contemplated by~~ (y) the ~~parties;~~number ~~the failure~~ of ~~shareholders~~shares of SXC orCommon ~~Catalyst~~Stock (decreased to ~~approve~~ the ~~proposed~~nearest ~~transaction;~~full ~~disruption~~share) ~~from~~equal ~~the proposed transaction making it more difficult~~ to ~~maintain business and operational relationships;~~ the ~~risk~~product of ~~customer attrition;~~ the exchange ~~possibility that the proposed transaction does not close~~ratio, ~~including,~~multiplied ~~but~~by ~~not limited to, due to~~ the ~~failure~~number toof ~~satisfy~~shares ~~the~~of ~~closing~~Company ~~conditions;~~Common ~~and~~Stock ~~the~~subject ~~ability~~ to ~~obtain~~such ~~the~~Company ~~financing~~warrant ~~contemplated~~immediately toprior ~~fund a portion of the consideration~~ to ~~be paid in~~ the ~~proposed~~Effective ~~transaction and the terms of such financing~~Time.

~~Important~~SXC ~~Additional~~and ~~Information~~the Company will each treat the Merger and the Subsequent Merger, taken together, as a “reorganization” under Section 368(a) of the Internal Revenue Code. For a discussion of the qualification of the Merger and the Subsequent Merger, taken together, as a “reorganization,” and the material U.S. federal income tax consequences of the exchange of Company Common Stock for SXC Common Stock and cash in the Merger, see the discussion under the heading “Taxation—Material U.S. Federal Income Tax Consequences” in the Registration Statement. Under the Merger Agreement, the Subsequent Merger would occur, and the parties would treat the Merger and the Subsequent Merger, taken together, as a “reorganization,” only if on or before the closing date each of SXC and the Company received an opinion of its special counsel as to certain tax matters specified in the merger agreement. SXC and the Company each received such an opinion on the closing date.

~~This~~Item ~~communication~~3.01 ~~does~~Notice ~~not~~of ~~constitute~~Delisting ~~an offer to sell~~ or ~~the~~Failure ~~solicitation of an offer~~ to ~~buy~~Satisfy ~~any securities or~~ a ~~solicitation~~Continued ofListing ~~any~~Rule ~~vote~~ or ~~approval. This~~Standard; ~~communication~~Transfer ~~is being made in respect~~ of ~~the proposed transaction involving Catalyst and SXC~~Listing. The proposed transaction will be submitted to the shareholders of Catalyst and the shareholders of SXC for their consideration. On June 1, 2012, the SEC declared effective the joint proxy statement/prospectus included in the registration statement on Form S-4 filed by SXC. On or about June 4, 2012, Catalyst and SXC commenced mailing of the definitive joint proxy statement/prospectus regarding the proposed transaction. Each of the companies may be filing with the SEC other documents regarding the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS, INVESTORS AND SECURITY HOLDERS OF CATALYST AND/OR SXC ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of the joint proxy statement/prospectus and other documents containing important information about Catalyst and SXC, through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by SXC will be available free of charge on SXC’s website at www.sxc.com under the heading “Investor Information” or by contacting SXC’s Investor Relations Department at 630-577-3100. Copies of the documents filed with the SEC by Catalyst will be available free of charge on Catalyst’s website at www.catalysthealthsolutions.com under the heading “Investor Information” or by contacting Catalyst’s Investor Relations Department at 301-548-2900. In addition, investors and security holders of Catalyst may obtain free copies of the joint proxy statement/prospectus filed with the SEC by directing a written request to:

~~MacKenzie~~In ~~Partners~~connection with the Merger, ~~Inc~~on July 2, 2012, the Company notified Nasdaq Stock Market LLC (“NASDAQ”) of its intent to remove its common stock from listing. On July 2, 2012, NASDAQ filed a delisting application on Form 25 with the SEC to delist and deregister the Company Common Stock. The Company intends to file a Form 15 to suspend its reporting obligations under Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, as soon as practicable.

~~105~~Item ~~Madison~~3.03 ~~Avenue~~Material Modification to Rights of Security Holders

~~New~~Pursuant ~~York~~to the terms of the Merger Agreement, ~~New~~at ~~York~~the ~~10016~~Effective Time, all shares of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than shares of Company Common Stock for which appraisal rights were properly exercised or shares of Company Common Stock owned by the Company, SXC, US Corp., Merger Sub, Merger LLC or any of their respective wholly-owned subsidiaries) were converted into the right to receive the Merger Consideration.

~~Stockholders~~Upon ~~May~~the ~~Call~~Effective ~~Toll-Free:~~Time, ~~(800)~~holders of shares of Company Common Stock ceased to have any rights as stockholders in the Company, other than the right to receive the Merger Consideration in accordance with the Merger Agreement or, in the case of shares of Company Common Stock held of record by stockholders who have properly demanded appraisal of such shares in accordance with Section ~~322-2885~~262 of the DGCL, appraisal rights.

~~Banks &~~The ~~Brokers~~information ~~May~~in ~~Call~~Item 2.01 ~~Collect:~~is incorporated ~~(212) 929-5500~~herein by reference.

~~SXC,~~Item ~~Catalyst~~5.01. ~~and~~Changes ~~certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants~~ in ~~the~~Control ~~solicitation~~ of ~~proxies in~~ Registrant

The information contained in Item 2.01 is incorporated herein by reference.

~~connection~~Item ~~with the proposed transaction~~5.02 ~~Information~~Departure ~~about the directors and executive officers~~ of ~~SXC~~Directors isor ~~set~~Certain ~~forth~~Officers; inElection ~~its proxy statement for its 2012 annual meeting~~ of ~~stockholders,~~Directors; ~~which~~Appointment ~~was filed with the SEC on April 2, 2012. Information about the directors and executive officers~~ of ~~Catalyst~~Certain isOfficers; ~~set~~Compensatory ~~forth~~Arrangements ~~in its proxy statement for its 2012 annual meeting~~ of ~~shareholders,~~Certain ~~which was filed with the SEC on April 26, 2012~~Officers. These documents can be obtained free of charge from the sources indicated above. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC.

~~Item~~At 9the Effective Time, all of the members of the board of directors of the Company resigned and were replaced by Mark Thierer and Jeffrey Park pursuant to the terms of the Merger Agreement.01 Additionally, David T. Blair, Timothy R. Pearson and Benjamin R. Preston resigned from their positions as officers of the Company. Following completion of the Merger, Mark Thierer was appointed as President and Chief Executive Officer of the Company, and Jeffrey Park was appointed as Chief Financial ~~Statements~~Officer, Executive Vice President—Finance, Secretary and ~~Exhibits~~Treasurer.

~~(a)—(c)~~Item ~~Not applicable~~5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Pursuant to the Merger Agreement, at the Effective Time, the: (di) Certificate ~~Exhibits:~~of Incorporation of the Company, as in effect immediately prior to the Effective Time, was amended and restated and (ii) Bylaws of Merger Sub, as in effect immediately prior to the Merger, became the Bylaws of the Company. A copy of the Amended and Restated Certificate of Incorporation is filed as Exhibit 3.1 hereto and is incorporated herein by reference. A copy of the Bylaws of the Company is filed as Exhibit 3.2 hereto and is incorporated herein by reference. As noted above, following the Merger, the Subsequent Merger was effected with the Company merging into Merger LLC and Merger LLC surviving the merger as a wholly-owned subsidiary of SXC. As a result of the Subsequent Merger, the surviving company’s name was changed to Catamaran Health Solutions, LLC and the Certification of Formation and Operating Agreement of the surviving company were amended. A copy of the Certificate of Formation and the Operating Agreement of the surviving company are filed herewith as Exhibit 3.3 hereto and Exhibit 3.4 hereto, respectively.

Exhibit Number		Description of Exhibit
2.1		Amendment to Agreement and Plan of Merger, dated as of June 29, 2012, by and among SXC Health Solutions Corp., SXC Health Solutions, Inc., Catamaran I Corp., Catamaran II LLC and Catalyst Health Solutions, Inc.

~~SIGNATURES~~Item 5.07 Submission of Matters to a Vote of Security Holders.

~~Pursuant~~(a) toOn July 2, 2012, Catalyst held a special meeting of its stockholders (the ~~requirements~~“Special Meeting”). At the Special Meeting, Catalyst stockholders approved the adoption of the ~~Securities~~Merger ~~Exchange~~Agreement. ~~Act~~Sufficient votes were received to approve the proposal for the adjournment of ~~1934~~the Special Meeting (if necessary or appropriate to solicit additional proxies if there were not sufficient votes to adopt the Merger Agreement), but an adjournment was not necessary in light of the ~~registrant~~adoption ~~has~~of ~~duly~~the ~~caused~~Merger ~~this~~Agreement. ~~report~~In addition, the non-binding advisory vote to beapprove ~~signed~~certain oncompensation ~~its~~arrangements ~~behalf~~for byCatalyst’s named executive officers in connection with the ~~undersigned~~Merger ~~hereunto~~was ~~duly~~also ~~authorized~~approved by Catalyst stockholders.

~~CATALYST~~(b) ~~HEALTH~~There ~~SOLUTIONS~~were 50,298,702 ~~INC.~~shares of ~~By:~~Catalyst ~~/s/~~common ~~Benjamin~~stock R.issued ~~Preston~~and ~~Name:~~outstanding ~~Benjamin~~on R.the ~~Preston~~record ~~Title:~~date ~~General~~and ~~Counsel~~eligible to be voted at the Special Meeting and 44,418,082 shares represented in person or by proxy at the Special Meeting, which constituted a quorum to conduct business at the Special Meeting.

~~Date:~~The ~~June 29,~~items ~~2012~~voted upon at the Special Meeting and the final voting results for each proposal were as follows:

1. To adopt the Merger Agreement.


For	Against		Abstain
44,395,085		19,583		3,441

2. To approve, by non-binding advisory vote, certain compensation arrangements for Catalyst’s named executive officers in connection with the merger contemplated by the Merger Agreement.


For	Against		Abstain
37,383,170		6,662,638		372,274

~~EXHIBIT~~Item 9.01 ~~INDEX~~Financial Statements and Exhibits

Exhibit Number		Description of Exhibit
2.1		Amendment to Agreement and Plan of Merger, dated as of June 29, 2012, by and among SXC Health Solutions Corp., SXC Health Solutions, Inc., Catamaran I Corp., Catamaran II LLC and Catalyst Health Solutions, Inc.

(d)

Exhibits


Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation of the Company

3.2		Bylaws of the Company

3.3		Amended Certificate of Formation of Catamaran Health Solutions, LLC

3.4		Amended and Restated Operating Agreement of Catamaran Health Solutions, LLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


CATAMARAN HEALTH SOLUTIONS, LLC,
successor by merger to Catalyst Health Solutions, Inc.

By:		/s/ Jeffrey Park
Name:		Jeffrey Park
Title:		Chief Financial Officer, Executive Vice President - Finance, Secretary and Treasurer

Date: July 6, 2012

INDEX TO EXHIBITS


Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation of the Company

3.2		Bylaws of the Company

3.3		Amended Certificate of Formation of Catamaran Health Solutions, LLC

3.4		Amended and Restated Operating Agreement of Catamaran Health Solutions, LLC

Filing Compare · CATALYST HEALTH SOLUTIONS, INC.